RT Journal Article SR Electronic T1 Early Detection of Lung Cancer in the NLST Dataset* JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.03.01.23286632 DO 10.1101/2023.03.01.23286632 A1 Mukherjee, Pritam A1 Brezhneva, Anna A1 Napel, Sandy A1 Gevaert, Olivier YR 2023 UL http://medrxiv.org/content/early/2023/03/02/2023.03.01.23286632.abstract AB Lung Cancer is the leading cause of cancer mortality in the U.S. The effectiveness of standard treatments, including surgery, chemotherapy or radiotherapy, depends on several factors like type and stage of cancer, with the survival rate being much worse for later cancer stages. The National Lung Screening Trial (NLST) established that patients screened using low-dose Computed Tomography (CT) had a 15 to 20 percent lower risk of dying from lung cancer than patients screened using chest X-rays. While CT excelled at detecting small early stage malignant nodules, a large proportion of patients (> 25%) screened positive and only a small fraction (< 10%) of these positive screens actually had or developed cancer in the subsequent years. We developed a model to distinguish between high and low risk patients among the positive screens, predicting the likelihood of having or developing lung cancer at the current time point or in subsequent years non-invasively, based on current and previous CT imaging data. However, most of the nodules in NLST are very small, and nodule segmentations or even precise locations are unavailable. Our model comprises two stages: the first stage is a neural network model trained on the Lung Image Database Consortium (LIDC-IDRI) cohort which detects nodules and assigns them malignancy scores. The second part of our model is a boosted tree which outputs a cancer probability for a patient based on the nodule information (location and malignancy score) predicted by the first stage. Our model, built on a subset of the NLST cohort (n = 1138) shows excellent performance, achieving an area under the receiver operating characteristics curve (ROC AUC) of 0.85 when predicting based on CT images from all three time points available in the NLST dataset.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNIH grants U01 CA1964050 and U01 CA187947Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NLST: https://wiki.cancerimagingarchive.net/display/NLST/National+Lung+Screening+TrialLIDC: https://wiki.cancerimagingarchive.net/pages/viewpage.action?pageId=1966254I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWe used publicly available data which can be found here:NLST: https://wiki.cancerimagingarchive.net/display/NLST/National+Lung+Screening+TrialLIDC: https://wiki.cancerimagingarchive.net/pages/viewpage.action?pageId=1966254https://wiki.cancerimagingarchive.net/display/NLST/National+Lung+Screening+Trialhttps://wiki.cancerimagingarchive.net/pages/viewpage.action?pageId=1966254